Navigation Links
Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research

ANN ARBOR, Mich., Oct. 30 /PRNewswire/ -- NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the addition of Joyce Sutcliffe, Ph.D., as vice president of research.

Sutcliffe brings 26 years of experience in the discovery and design of new antibiotics, with particular emphasis on understanding and overcoming antibiotic resistance. She joined the NanoBio team from Rib-X Pharmaceuticals, where she served as vice president of biology and chief research scientist.

During her tenure at Rib-X Pharmaceuticals and previously at Pfizer and Abbott, Sutcliffe focused on leveraging knowledge about target-based resistance to help design novel antibiotics that are potent against organisms with antibiotic resistance. She also led teams that evaluated efficacy and pharmacokinetics in animal disease models to ensure safety and compatibility with other drugs.

"Antibiotic resistance drives the need for new treatments against tenacious infectious microorganisms that continue to mutate," said Sutcliffe. "For example the rampant explosion of MRSA (methicillin-resistant Staphylococcus aureus) in the community has led to a need for safe anti- infectives. These bacteria are no longer resistant to just antibiotics but have become multidrug-resistant by adding other resistance mechanisms to their armamentarium.

"NanoBio's deep pipeline of topical anti-infectives and mucosal vaccines is particularly compelling, given the platform technology poses a very low risk of resistance while having broad antimicrobial activity against a wide range of infections," Sutcliffe said.

NanoBio's line of anti-infectives are designed to wage a two-pronged attack against bacteria, viruses, and fungi using safe detergents along with high-energy nanoemulsions to physically disrupt pathogen membranes and lyse microbes, said James Baker, Jr., M.D., founder and CSO of NanoBio Corporation. The absence of a specific metabolic target significantly reduces the likelihood of triggering resistant infections, he added.

"The addition of Dr. Sutcliffe, an internationally recognized anti- infective expert, will enable NanoBio to accelerate the number of product candidates we take into the clinic for preventing and treating a wide range of infections," said Baker.

About NanoBio

NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

SOURCE NanoBio Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Chemical-petroleum executive joins Virent Energy board
2. Schneider National exec joins TrafficCast board
3. Doyle joins governors in support of stem cell bill
4. Genomics researcher Hood joins NimbleGen board
5. Fergus joins Baird Venture Partners, Caden Bio
6. Meier joins Broadlook Technologies as COO
7. Prodesse joins forces with Invitrogen
8. Wisconsin joins price-fixing suit vs. D-RAM makers
9. Napier joins board of Third Wave Technologies
10. Schmidt rejoins Renaissance Learning
11. Tommy Thompson joins drug company as advisor
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 27th Annual ... . .   Listeners ... prior to the presentation to download or install any ... available on the website approximately one hour after the ...
(Date:11/25/2015)... 25, 2015 The Global ... a professional and in-depth study on the current ... (Logo: ) , The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ...
(Date:11/24/2015)... Cepheid (NASDAQ: CPHD ) today announced ... conference, and invited investors to participate via webcast. ... December 1, 2015 at 11.00 a.m. Eastern Time ... December 1, 2015 at 11.00 a.m. Eastern Time ... York, NY      Tuesday, December 1, 2015 at ...
Breaking Biology Technology:
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/26/2015)... and LAS VEGAS , Oct. 26, ... , an innovator in modern authentication and a founding ... the launch of its latest version of the Nok ... organizations to use standards-based authentication that supports existing and ... Authentication Suite is ideal for organizations deploying customer-facing applications ...
Breaking Biology News(10 mins):